Zacks Investment Research downgraded shares of Urogen Pharma (NASDAQ:URGN) from a hold rating to a sell rating in a research note published on Wednesday morning.

According to Zacks, “UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company’s product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra’anana, Israel. “

URGN has been the topic of a number of other research reports. Oppenheimer set a $75.00 target price on shares of Urogen Pharma and gave the company a buy rating in a research note on Tuesday, August 14th. Stifel Nicolaus started coverage on shares of Urogen Pharma in a research note on Thursday, September 13th. They issued a buy rating and a $70.00 target price on the stock. Finally, Cowen reissued a buy rating on shares of Urogen Pharma in a research note on Tuesday, August 14th. One equities research analyst has rated the stock with a sell rating and nine have given a buy rating to the company’s stock. The company has an average rating of Buy and a consensus target price of $65.25.

NASDAQ:URGN opened at $41.93 on Wednesday. Urogen Pharma has a 52-week low of $25.56 and a 52-week high of $69.57.

Urogen Pharma (NASDAQ:URGN) last posted its earnings results on Tuesday, August 14th. The company reported ($1.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.89) by ($0.25). The business had revenue of $0.36 million during the quarter. Urogen Pharma had a negative net margin of 470.54% and a negative return on equity of 44.24%. As a group, equities research analysts forecast that Urogen Pharma will post -4.12 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of URGN. Menora Mivtachim Holdings LTD. increased its stake in Urogen Pharma by 35.5% in the first quarter. Menora Mivtachim Holdings LTD. now owns 2,045,629 shares of the company’s stock valued at $101,647,000 after acquiring an additional 535,622 shares during the period. Citadel Advisors LLC increased its stake in Urogen Pharma by 294.6% in the second quarter. Citadel Advisors LLC now owns 321,034 shares of the company’s stock valued at $15,974,000 after acquiring an additional 239,676 shares during the period. Millennium Management LLC increased its stake in Urogen Pharma by 1,285.4% in the first quarter. Millennium Management LLC now owns 159,113 shares of the company’s stock valued at $7,906,000 after acquiring an additional 147,628 shares during the period. BlackRock Inc. bought a new stake in Urogen Pharma in the second quarter valued at about $4,468,000. Finally, Bainco International Investors increased its stake in Urogen Pharma by 67.2% in the second quarter. Bainco International Investors now owns 175,461 shares of the company’s stock valued at $8,731,000 after acquiring an additional 70,500 shares during the period. 71.11% of the stock is currently owned by institutional investors and hedge funds.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

See Also: Stock Symbols Definition, Examples, Lookup

Get a free copy of the Zacks research report on Urogen Pharma (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.